Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer
80
about 8.1 years
18+
Male only
1 site in PA
What this study is about
Researchers are testing if adaptive stereotactic body radiation therapy (SBRT) with a SIB is safe and effective to treat prostate cancer in men. The trial will assess the safety of this treatment over time, including side effects and quality of life.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive adaptive stereotactic body radiation therapy (SBRT) with a SIB
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Severe (CTCAE grade ≥ 3) treatment-related (possibly, probably or definitely) toxicity occurring within 90 days of treatment.
Secondary: Biochemically progression free survival, Distant metastasis free survival
radiation
Oncology